Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria.

Yuki NemotoHiroki IshiharaKazutaka NakamuraHidekazu TachibanaHironori FukudaKazuhiko YoshidaHirohito KobayashiJunpei IizukaHiroaki ShimmuraYasunobu HashimotoKazunari TanabeTsunenori KondoToshio Takagi

Published in: Targeted oncology (2022)

There are many trial-ineligible patients in the real world. Nevertheless, the efficacy and safety of ICI-based combination therapy in trial-ineligible patients were non-inferior compared with those of trial-eligible patients.

Keyphrases

end stage renal disease
ejection fraction
clinical trial
study protocol
combination therapy
prognostic factors
randomized controlled trial
phase ii